BioAge Labs is a clinical-stage biopharmaceutical company developing drugs for cardiometabolic disease by targeting biological pathways linked to human aging. Its pipeline includes small-molecule programs such as an oral NLRP3 inhibitor aimed at inflammation-driven cardiovascular risk and APJ receptor agonists explored as exercise-mimetic approaches for obesity. The company draws on human aging data and multi-omics insights to select targets rather than pursuing classical single-disease screens alone. It remains largely pre-revenue, with activity centered on clinical development.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2.4 | — | -21.6 | — |
| Q3 2025 | 2 | — | -20.2 | — |
| Q4 2025 | 3.1 | — | -25.9 | — |
| Q1 2026 | 2.8 | — | -22.3 | — |
| Q2 2026 | 2.5 | 1.6% | -26.1 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Akebia Therapeutics, Inc. (AKBA), Spok Holdings, Inc. (SPOK), Sionna Therapeutics, Inc. (SION), ioneer Ltd (IONR), Irenic Acquisition Corp. (IACQU), Imperial Petroleum Inc. (IMPP)